DENOVO BIOPHARMA acquired enzastaurin from Eli Lilly and Co. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.
DAVID TWEARDY was named division head of internal medicine of MD Anderson Cancer Center effective Dec. 1.
SUTRO BIOPHARMA and the biopharmaceutical division of Merck KGaA in Darmstadt, Germany, which operates as EMD Serono in the U.S. and Canada, announced a collaboration and license agreement to develop antibody drug conjugates.
SOLIGENIX INC. reached an agreement with FDA on the design of a phase III clinical trial evaluating SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma.
BOEHRINGER INGELHEIM and CureVac announced an exclusive global license and development collaboration focused on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.
MEMORIAL SLOAN KETTERING CANCER CENTER began construction on a 285,000-square-foot outpatient cancer treatment facility in Middletown, N.J., with plans to open in late 2016.
DAN GLICKMAN was named to the board of directors of the American Cancer Society Cancer Action Network.
STANFORD UNIVERSITY began an online Genetics and Genomics Certificate program, available through the university's School of Medicine and School of Engineering. Courses will be taught by faculty from the Department of Genetics and guest lecturers.
LOUIS DEGENNARO was named president and CEO of the Leukemia and LymphomaSociety.
GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER received a five-year, $11.25 million P30 Cancer Center Support Grant and renewal of its designation as a comprehensive cancer center.
